Characteristics of the patients treated with VRD (N = 34)
| . | Values . |
|---|---|
| Age, median (range), y | 66.5 (46-84) |
| Male/female, % | 68/32 |
| Organ involvement, % | |
| Heart | 79 |
| Renal | 54.5 |
| Liver | 21 |
| PNS/ANS | 21 |
| Mayo stage 1/2/3A/3B, % | 12/50/15/23 |
| dFLC, median (range) | 170 (6-7228) |
| BM PCs, median (range) | 15 (0-30) |
| Cytogenetics (n = 28), n (%) | |
| t(11;14) | 7 (25) |
| Del17p | 1 (3) |
| t(4;14) | 0 |
| t(14;16) | 2 (7) |
| amp/add 1q21 | 4(14) |
| Del13q | 13 (46) |
| None of the above | 9 (32) |
| eGFR*, median (range)/eGFR <30 mL/min/1.73 m2, n (%) | 65 (10-133)/8 (23.5) |
| Renal stage 1/2/3 (within patients with renal involvement), % | 11/50/39 |
| Proteinuria (g)/24 h, median (range) | 7.96 (1.4-18) |
| . | Values . |
|---|---|
| Age, median (range), y | 66.5 (46-84) |
| Male/female, % | 68/32 |
| Organ involvement, % | |
| Heart | 79 |
| Renal | 54.5 |
| Liver | 21 |
| PNS/ANS | 21 |
| Mayo stage 1/2/3A/3B, % | 12/50/15/23 |
| dFLC, median (range) | 170 (6-7228) |
| BM PCs, median (range) | 15 (0-30) |
| Cytogenetics (n = 28), n (%) | |
| t(11;14) | 7 (25) |
| Del17p | 1 (3) |
| t(4;14) | 0 |
| t(14;16) | 2 (7) |
| amp/add 1q21 | 4(14) |
| Del13q | 13 (46) |
| None of the above | 9 (32) |
| eGFR*, median (range)/eGFR <30 mL/min/1.73 m2, n (%) | 65 (10-133)/8 (23.5) |
| Renal stage 1/2/3 (within patients with renal involvement), % | 11/50/39 |
| Proteinuria (g)/24 h, median (range) | 7.96 (1.4-18) |
BM, bone marrow; PC, plasma cell; PNS/ANS, peripheral nervous system/autonomic nervous system.
All patients in the study; among those with renal involvement, the median eGFR was 59 mL/min/1.73 m2.